MedTrace Logo

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism

NCT05686993 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-07-08

No results posted yet for this study

Summary

The goal of this pilot, open-label prospective study is to evaluate if the effect of calcium channel blockade on plasma aldosterone levels in people with primary aldosteronism (PA) is due primarily to Cav1.3 blockade.

This will be tested by treating participants who have PA with both cinnarizine (Cav1.3 blocker) and nifedipine (Cav1.2 blocker) and evaluating effect on aldosterone levels and blood pressure over a two week course of treatment.

Conditions

  • Primary Aldosteronism
  • Endocrine Hypertension

Interventions

DRUG

Cinnarizine

Cinnarizine oral 30mg TDS

DRUG

NIFEdipine ER

Nifedipine oral 60mg daily extended release

Sponsors & Collaborators

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Morris Brown, MD FRCP · Queen Mary University of London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-24
Primary Completion
2023-09-01
Completion
2023-09-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686993 on ClinicalTrials.gov